Group 1 - The company has approved a share repurchase plan with a total funding amount between RMB 50 million and RMB 100 million, with a maximum repurchase price of RMB 6.95 per share [1][2] - The repurchase will be conducted through centralized bidding and aims to cancel the repurchased shares, thereby reducing the registered capital of the company [1] - The repurchase period is set for a maximum of 6 months from the date of the shareholders' meeting approval [1] Group 2 - The company has obtained a loan commitment letter from the Bank of China, with a maximum loan amount of RMB 90 million and a loan term not exceeding 3 years [2] - The loan is intended to support the company's share repurchase activities [2] - The actual repurchase amount will be determined based on the market conditions and the availability of funds at the end of the repurchase period [2]

亚宝药业集团股份有限公司 关于取得金融机构股票回购贷款承诺函的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、回购股份方案的基本情况 亚宝药业集团股份有限公司（以下简称"公司"）于 2025 年 5 月 16 日召开 了 2024 年年度股东大会，审议通过了《关于以集中竞价交易方式回购股份方案 的议案》，同意公司以集中竞价方式回购公司股份，回购股份的资金总额不低于 人民币 0.5 亿元（含）且不超过人民币 1 亿元（含），回购股份价格不超过人民 币 6.95 元/股，回购用途为全部予以注销并减少公司注册资本，回购期限为自股 东大会审议通过回购方案之日起不超过 6 个月，本次回购资金来源为公司自有资 金及自筹资金。具体内容详见公司于 2025 年 5 月 17 日在上海证券交易所网站 （www.sse.com.cn）及《中国证券报》《上海证券报》上发布的《亚宝药业集团 股份有限公司关于以集中竞价交易方式回购股份的回购报告书》（公告编号： 2025-020）。 二、取得金融机构股票回购贷款承诺函的情况 近日，公司取得中国 ...

亚宝药业（600351）公告，公司近日取得中国银行股份有限公司运城市分行出具的《贷款承诺函》，承 诺贷款金额最高不超过9000万元，贷款期限不超过3年，贷款用途为股票回购。此前，公司于2025年5月 16日召开的2024年年度股东大会审议通过了以集中竞价方式回购股份的议案，回购资金总额不低于0.5 亿元且不超过1亿元，回购价格不超过6.95元/股，回购用途为全部予以注销并减少公司注册资本，回购 期限为不超过6个月，资金来源为公司自有资金及自筹资金。 ...

Core Viewpoint - The announcement from the Shanxi Provincial Drug Administration details the results of GMP compliance inspections for 14 pharmaceutical manufacturing companies, indicating their adherence to national drug production standards [2]. Group 1: Inspection Results - The inspection results include companies such as China National Pharmaceutical Group Weichida Pharmaceutical Co., Ltd., which was inspected for hard capsule production of penicillin oral preparations [3]. - Other companies listed include Shanxi Huida Pharmaceutical Co., Ltd. and Shanxi Zhongyuan Pharmaceutical Co., Ltd., with various products ranging from oral solutions to traditional Chinese medicine pieces being evaluated for compliance [3][4]. - The inspections were conducted between January 16 and March 31, 2025, with all companies listed achieving compliance [3][4]. Group 2: Compliance Details - The compliance checks were based on the Drug Administration Law of the People's Republic of China and related regulations, ensuring that the inspected companies meet the required quality management standards [2]. - Specific products inspected include oral solutions, hard capsules, and raw materials, with detailed addresses and production lines provided for each company [3][4]. - The results signify a commitment to maintaining high standards in pharmaceutical production within the region, which is crucial for public health and safety [2].

Group 1 - The company will hold a performance briefing for the fiscal year 2024 and the first quarter of 2025 on June 9, 2025, from 15:00 to 17:00 [1][2] - The briefing will be conducted via video live streaming and online interaction at the Shanghai Stock Exchange Roadshow Center [2][3] - Investors can submit questions from May 30, 2025, to June 6, 2025, through the Roadshow Center website or via the company's email [3] Group 2 - Key personnel attending the briefing include the Chairman, Secretary of the Board, Chief Financial Officer, and an Independent Director [2] - After the briefing, investors can view the main content and details of the event on the Shanghai Stock Exchange Roadshow Center [3]

重要内容提示： 投资者可于 2025 年 05 月 30 日 （星期五） 至 06 月 06 日 （星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 wangyu@yabaoyaoye.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 亚宝药业集团股份有限公司（以下简称"公司"）已于 2025 年 4 月 26 日发 布公司 2024 年年度报告和 2025 年第一季度报告，便于广大投资者更全面深入地 了解公司 2024 年度及 2025 年第一季度的经营成果、财务状况，公司计划于 2025 年 06 月 09 日 （星期一） 15:00-17:00 举行 2024 年度暨 2025 年第一季度业绩 说明会，就投资者关心的问题进行交流。 证券代码：600351 证券简称：亚宝药业 公告编号：2025-024 亚宝药业集团股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （二） 会议召开地点：上证路 ...

Core Points - The company announced a cash dividend of 0.3 CNY per share for its A shares, totaling approximately 210 million CNY to be distributed to shareholders [1][2][3] - The dividend distribution plan was approved at the annual shareholders' meeting held on May 16, 2025 [1][2] - Key dates for the dividend distribution include the record date on May 29, 2025, and the ex-dividend date on May 30, 2025 [2][3] Dividend Distribution Details - The total share capital of the company is 700,000,046 shares, and the cash dividend will be distributed based on this total [1][2] - For individual shareholders and securities investment funds, no income tax will be withheld at the time of dividend distribution; tax will be calculated based on the holding period when shares are sold [3][4] - For qualified foreign institutional investors (QFII), a 10% withholding tax will apply, resulting in a net dividend of 0.27 CNY per share [3][4] - For Hong Kong Stock Exchange investors, the same 10% withholding tax applies, leading to a net dividend of 0.27 CNY per share [3][4] - Resident corporate shareholders are responsible for their own tax payments, receiving the full dividend of 0.3 CNY per share [3][4]

亚宝药业集团股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600351 证券简称：亚宝药业 公告编号：2025-023 重要内容提示： 每股分配比例 A 股每股现金红利0.3元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/5/29 | － | 2025/5/30 | 2025/5/30 | 差异化分红送转： 否 一、 通过分配方案的股东会届次和日期 四、 分配实施办法 1. 实施办法 无限售条件流通股的红利委托中国结算上海分公司通过其资金清算系统向股权登记日上 海证券交易所收市后登记在册并在上海证券交易所各会员办理了指定交易的股东派发。已办 理指定交易的投资者可于红利发放日在其指定的证券营业部领取现金红利，未办理指定交易 的股东红利暂由中国结算上海分公司保管，待办理指定交易后再进行派发。 本次利润分配方案经公司2025 年 5 月 ...

Core Viewpoint - The company plans to repurchase shares through a centralized bidding method, with a total repurchase amount ranging from RMB 0.5 billion to RMB 1 billion, aimed at enhancing shareholder value and confidence in the company's future prospects [1][5][10]. Summary by Sections Repurchase Plan Details - The repurchase plan was first disclosed on April 26, 2025, and will be implemented within six months after approval by the shareholders' meeting [4]. - The repurchase will involve buying back between 7,194,244 and 14,388,489 shares, representing 1.03% to 2.06% of the total share capital [4][7]. - The maximum repurchase price is set at RMB 6.95 per share, which is 150% of the average trading price over the 30 trading days prior to the board's decision [2][6]. Purpose and Funding - The purpose of the repurchase is to maintain company value and protect shareholder interests, with the repurchased shares to be canceled to reduce registered capital [4][10]. - The funding for the repurchase will come from the company's own funds and self-raised funds [5][7]. Financial Impact - If the maximum repurchase amount of RMB 1 billion is utilized, it would account for approximately 2.80% of the company's total assets, 3.40% of net assets attributable to shareholders, and 6.20% of current assets as of March 31, 2025 [9][10]. - The company believes that the repurchase will not significantly impact its operations, finances, or future development [10]. Shareholder Considerations - The company has confirmed that there are no plans for share reductions by major shareholders in the next three to six months [10][11]. - The repurchase plan requires approval from the shareholders' meeting and must comply with creditor notifications to protect their interests [12]. Implementation and Adjustments - The repurchase will be executed through the Shanghai Stock Exchange trading system, and adjustments to the repurchase price may occur due to corporate actions like dividends or stock splits [6][7]. - The company has established a dedicated securities account for the repurchase [12].

Group 1 - The legal opinion letter confirms that the 2024 annual general meeting of shareholders for Yabao Pharmaceutical Group Co., Ltd. was convened and conducted in accordance with relevant laws and regulations [4][9] - The meeting was scheduled for May 16, 2025, and was announced on April 26, 2025, with all necessary documentation provided [5][6] - The meeting was attended by 4 shareholders in person, representing 63,988,100 shares, and 367 participants voted online, representing 169,190,891 shares, which accounted for 24.1701% of the total shares [7] Group 2 - The qualifications of attendees included all shareholders registered by May 9, 2025, along with directors, supervisors, senior management, and invited guests [6][7] - No new proposals were submitted by shareholders during the meeting [8] - Voting was conducted through both in-person and online methods, with results confirming that all resolutions passed met the required majority [8][9]